Start-Ups & SMEs
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
![](/-/media/editorial/scrip/2024/06/sc062024_1909870405_-blue-shoot.jpg?rev=69980cee87f64612ba92093dfa34f2cc&w=350&hash=7D1B55C6E996AB4B4342215675AD1516)
Ashibio Takes Shelved Gilead Drug In New Direction
On the back of a “truly one in a million” case, Ashibio has revived research into Gilead's discontinued asset andecaliximab after it showed promise in the ultra-rare musculoskeletal condition FOP.
![](/-/media/editorial/scrip/2024/06/sc2406_startupbabyblue_2358722117_1200.jpg?rev=306ec52eabf4449f85835683ffa5eab5&w=350&hash=C2850B4CD2B138370DF42129913E01B7)
Ensho Joins Race To Develop An Oral Integrin Inhibitor For IBD
Ensho Therapeutics is raising series A cash to develop Phase II-ready NSHO-101 (EA1080), a third oral ɑ4β7 integrin inhibitor attempting to take on Takeda’s blockbuster injectable Entyvio.
![](/-/media/editorial/scrip/2024/06/sma1.jpg?rev=495001795cd04b4ead0c63e07fa017ca&w=350&hash=78FD5E1ED4A74527935DBBDE1B11EA70)
Scholar Rock And Biohaven Get Ready To Flex Their Muscles In SMA
The companies are set to present Phase III results from their rival myostatin inhibitor drugs for spinal muscular atrophy in Q4, while also fast-tracking the candidates in obesity studies.
![](/-/media/editorial/scrip/00_regular-column-images/finance_watch_private_company_1200_675.jpg?rev=08e535103fc64137a8ebefc93306626d&w=350&hash=9AB8CAA21A02F4913A32E237402983A4)
Finance Watch: More Than $2.5bn In New VC Funding, Capital For Pharma Manufacturing In Africa
Private Company Edition: J.P. Morgan raised more than $500m in its first venture fund and the Africa Health Security Investment Plan gained $2bn. Also, Marea launched with $190m, Iambic’s series B expanded to $150m, InduPro raised an $85m series A and Elion closed an $81m series B.
![](/-/media/editorial/stock-images/biotech/rna-1200-shutterstock_2023325972.jpg?rev=5c6574a7db424e098ca6f262bf33fcdc&w=350&hash=EC7FB83FADC8DD9C187F13107F6EAF1D)
Roche Adds Ascidian’s RNA-Writing To Its Neurology Push
A first big pharma partnership for Ascidian, headed up by ex-Biogen research head Michael Ehlers, as the Swiss firm expands its gene editing and neuroscience efforts.
![](/-/media/editorial/scrip/00_regular-column-images/finance_watch_private_company_1200_675.jpg?rev=08e535103fc64137a8ebefc93306626d&w=350&hash=9AB8CAA21A02F4913A32E237402983A4)
Finance Watch: Lilly’s Gateway Labs, Deerfield’s Cure Offer Biotechs Space To Grow
Private Company Edition: Scrip spoke with the leaders of Gateway Labs and Cure at the BIO International Convention about their mini ecosystems. Also, radiopharmaceutical firm ITM raised €188m ($201.9m), Santa Ana Bio emerged with $168m and Alzheon’s series E totaled $100m.
![](/-/media/editorial/scrip/2024/06/sc2406_intestine_1452312020_1200.jpg?rev=0dc0674c0caf49ff939dcd4246b1cfd7&w=350&hash=F720BFE96BDF270BDABFECF604EA9345)
Syntis Bio Launches, Focusing On Oral Obesity Drugs And Rare Diseases
The company formed around technology from the labs of MIT’s Robert Langer and Giovanni Traverso and already has a lead asset in the clinic.
![](/-/media/editorial/scrip/00_regular-column-images/finance_watch_private_company_1200_675.jpg?rev=08e535103fc64137a8ebefc93306626d&w=350&hash=9AB8CAA21A02F4913A32E237402983A4)
Finance Watch: Two New VC Funds Bring $365m For Start-Ups
Private Company Edition: Amplitude Ventures raised $192m for its second fund, while XGEN Venture debuted with €160m ($173.4m). Also, hub-and-spoke biopharma operator CinRx added $73m, Adcendo extended its series A round to €98m ($106.2m) and Grey Wolf raised $50m.
![](/-/media/editorial/stock-images/biotech/adcs_shutterstock_2460470143.jpg?rev=2e4525577ef44220a368136e92442665&w=350&hash=FD2E223AA10001364AB86BC1F4EF7585)
Why Pheon Is Keeping Mum Over Target For Novel ADC
Intense competition in ADCs means Pheon is holding back details on its technology as it heads into Phase I studies after a $120m series B fundraising.
![](/-/media/editorial/scrip/2023/02/sc022023_adc_1200.jpg?rev=e6bb65a33729458caf3de41c6d07a680&w=350&hash=FF5DCDFEBE4E67CC5AC40CED569E31A2)
Mythic Therapeutics Faces An Acid Test
Emerging Company Profile: Efficacy data on the young group’s first pH-engineered antibody-drug conjugate could come next year, and potential partners will be watching.
![](/-/media/editorial/scrip/00_regular-column-images/finance_watch_private_company_1200_675.jpg?rev=08e535103fc64137a8ebefc93306626d&w=350&hash=9AB8CAA21A02F4913A32E237402983A4)
Finance Watch: AltruBio, Pheon Raise Venture Capital Mega-Rounds
Private Company Edition: AltruBio raised up to $225m and Pheon garnered $120m in series B financings, while Lycia brought in $106.6m in series C cash. Also, Sands Capital closed its third life science fund, totaling $555m, and NewVale Capital debuted with $167m for life science services.
![](/-/media/editorial/scrip/2024/05/sc2405_iitbuildingcapability_2385438955_1200.jpg?rev=63d4acdb75bd4991931ec5a0758a903b&w=350&hash=62C432C1F3C745554E8171795A031D37)
Alphabet To AI Connect, What Favors Drug Development At Indian Institutes Of Technology
After starring in India’s first CAR-T treatment, the country’s Indian Institutes of Technology, or IITs, are set to expand their drug development footprint. Scrip takes a look at what the Indian equivalents of the Massachusetts Institute of Technology have going for them, including sizeable funding and alumni like Alphabet's CEO.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.